Andrew Arnott
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Genetic Associations and Epidemiology
Papers in
-
- Intensive Care Unit Cognitive Disorders 2
-
- Anesthesia and Sedative Agents 2
In The Last Decade
Andrew Arnott
8 papers receiving 573 citations
Andrew Arnott's Hit Papers
Peers
Comparison fields: 5 of 56
- Infectious Diseases 307
- Genetics 94
- Critical Care and Intensive Care Medicine 10
- Immunology 35
- Neurology 21
Countries citing papers authored by Andrew Arnott
This map shows the geographic impact of Andrew Arnott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Arnott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Arnott more than expected).
Fields of papers citing papers by Andrew Arnott
This network shows the impact of papers produced by Andrew Arnott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Arnott. The network helps show where Andrew Arnott may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 2 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 3 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 4 | 2023 | 60 | |
| 5 | 2023 | 46 | |
| 6 | 2023 | 34 | |
| 7 | Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients Hit paper breakdown → | 2025 | 17 |
| 8 | 2025 | 1 |
About Andrew Arnott
Andrew Arnott is a scholar working on Critical Care and Intensive Care Medicine, Anesthesiology and Pain Medicine, Infectious Diseases, Genetics and Nutrition and Dietetics, having authored 8 papers that have together received 598 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (3 papers), Anesthesia and Sedative Agents (2 papers), Genetic Associations and Epidemiology (2 papers), Intensive Care Unit Cognitive Disorders (2 papers) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (307 citations), Genetics (94 citations), Critical Care and Intensive Care Medicine (10 citations), Immunology (35 citations) and Neurology (21 citations). Their work appears in journals such as JAMA, The Lancet, Nature and JAMA Network Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.